Allan Musinguzi

Infectious Diseases Research Collaboration

MedicineEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda”.

Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda

Implementation Science(2020)10.1186/s13012-020-01025-8

N/A

0.558DataRank · unranked

23 citations

Allan Musinguzi, Juliet Nabunje, Fred Welishe, Jackie Ssemata, Bishop Opira +16 more

Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial

PLoS Medicine(2024)10.1371/journal.pmed.1004356

N/A

0.478DataRank · unranked

11 citations

Jillian L. Kadota, Allan Musinguzi, Fred Welishe, Anne Nakitende, Lydia Akello +20 more

Adverse Events Reported During Weekly Isoniazid-Rifapentine (3HP) Tuberculosis Preventive Treatment Among People With Human Immunodeficiency Virus in Uganda

Open Forum Infectious Diseases(2024)10.1093/ofid/ofae667

N/A

0.282DataRank · unranked

4 citations

Allan Musinguzi, Hélène E. Aschmann, Lydia Akello, Fred Welishe, Jane Nakimuli +8 more

Evaluating the implementation of weekly rifapentine-isoniazid (3HP) for tuberculosis prevention among people living with HIV in Uganda: A qualitative evaluation of the 3HP Options Trial

PLOS Global Public Health(2024)10.1371/journal.pgph.0003347

N/A

0.241DataRank · unranked

4 citations

Joan Ritar Kasidi, Jillian L. Kadota, Fred Welishe, Anne Nakitende, Lydia Akello +20 more

Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda—patient and health worker perspectives

Implementation Science Communications(2021)10.1186/s43058-021-00173-2

N/A

0DataRank · unranked

22 citations

Allan Musinguzi, Jackie Ssemata, Fred Welishe, Juliet Nabunje, Jillian L. Kadota +8 more

Preferences of people living with HIV for features of tuberculosis preventive treatment regimens – a discrete choice experiment

medRxiv(2023)10.1101/2023.09.13.23295043

N/A

0DataRank · unranked

1 citations

Allan Musinguzi, Jillian L. Kadota, Catherine Namale, Juliet Kakeeto, Jane Nakimuli +9 more

Acceptance and Completion of Rifapentine-based TB Preventive Therapy (3HP) Among People Living with HIV (PLHIV) in Kampala, Uganda – Patient and Health Worker Perspectives.

Research Square(2020)10.21203/rs.3.rs-92783/v1

N/A

0DataRank · unranked

0 citations

Allan Musinguzi, Jackie Ssemata, Fred Welishe, Juliet Nabunje, Jillian L. Kadota +8 more

Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda

IJTLD OPEN(2024)10.5588/ijtldopen.23.0283

N/A

0DataRank · unranked

4 citations

Hélène E. Aschmann, Jillian L. Kadota, Jane Nakimuli, Fred Welishe, Juliet Kakeeto +11 more